Current and future strategies aiming at reducing catecholamine exposure in septic shock
Arthur Dubech, Adrien Picod, Alexandre Pierre, Sébastien Preau, Raphaël Favory, Bruno Garcia · 2026
Read Current and future strategies aiming at reducing catecholamine exposure in septic shock by Arthur Dubech, Adrien Picod, Alexandre Pierre, Sébastien Preau, Raphaël Favory, Bruno Garcia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13483425.txt.
Description
Arthur Dubech and co-authors offer a 2026 review of ways to cut catecholamine drug exposure in septic shock. Noradrenaline remains the first drug for holding blood pressure when infection crashes circulation, but long, heavy dosing strains the heart, metabolism, and immune system. The review weighs early dosing, pressure targets set by skin blood flow, and non-adrenaline stand-ins.
Vasopressin trims catecholamine need and lowers the odds of a racing, uneven heartbeat. Angiotensin II helps when standard drugs fail, perhaps most in kidney injury. Steroids restore vessel grip and speed weaning off the drip. Short-acting beta blockers, blue dye targeting vessel relaxation, and immune-calming add-ons each show narrower, mixed promise. The authors favour a personal, layered plan that guards tissue blood flow while shaving the adrenaline burden.
Catalog record
| CREATOR | Arthur Dubech, Adrien Picod, Alexandre Pierre, Sébastien Preau, Raphaël Favory, Bruno Garcia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59323 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |